homepage_cover_1Firm of Choice for the Most Difficult Legal Issues homepage_cover_2Cross-Border Capabilities with a China Edge NewsFangda Advises Qyuns Therapeutics on its Exclusive License Agreement with Caldera Therapeutics for the Development and Commercialization on Qx030nRead More Insight2024 Antitrust China Annual Review With rising investigation/litigation risks, shifting regulatory priorities, and an increasing emphasis on fair competition, businesses must stay ahead of these changes to manage compliance effectively.READ MORE Awards & RankingsChambers & Partners Global Guide 2024 Band 1 RankingsChambers & Partners Greater China Region Guide 2024 Band 1 RankingsRead More